Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings Companies Business Strategies

Bayer To Split Off Consumer Or Crop Science, Or Both, Or Neither

  • News

Executive Summary

After a miserable third quarter the German group is cutting jobs and considering splitting up, but concrete decisions are thin on the ground.

You may also be interested in...



Bayer Switches Focus Of Recursion AI Pact To Oncology

After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.

Merck KGaA Sticks With Structure, Eyes Smaller Healthcare Deals

There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.

Dupixent Heralds The Age Of Biologics In COPD

A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings Companies Business Strategies
Latest Headlines

Quick Listen: Scrip's Five Must-Know Things

Finance Watch: Though Flush With Cash, Theseus Seeks Alternatives, Gets Two Quick Offers

Roivant Won’t Continue With Brepocitinib In Lupus After Phase II Failure

Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain

See All
UsernamePublicRestriction

Register

SC149325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By